Research ArticleOriginal Research

Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease

Yet Hong Khor, Nicole SL Goh, Ian Glaspole, Anne E Holland and Christine F McDonald
Respiratory Care March 2019, 64 (3) 299-306; DOI: https://doi.org/10.4187/respcare.06334

References

  1. 1.↵
    1. King TE Jr.,
    2. Tooze JA,
    3. Schwarz MI,
    4. Brown KR,
    5. Cherniack RM
    . Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164(7):1171–1181.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Lama VN,
    2. Flaherty KR,
    3. Toews GB,
    4. Colby TV,
    5. Travis WD,
    6. Long Q,
    7. et al
    . Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168(9):1084–1090.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.
    1. Hallstrand TS,
    2. Boitano LJ,
    3. Johnson WC,
    4. Spada CA,
    5. Hayes JG,
    6. Raghu G
    . The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25(1):96–103.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Flaherty KR,
    2. Andrei AC,
    3. Murray S,
    4. Fraley C,
    5. Colby TV,
    6. Travis WD,
    7. et al
    . Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174(7):803–809.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Wallaert B,
    2. Monge E,
    3. Le Rouzic O,
    4. Wémeau-Stervinou L,
    5. Salleron J,
    6. Grosbois JM
    . Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest 2013;144(5):1652–1658.
    OpenUrlPubMed
  6. 6.↵
    1. Herridge J,
    2. Yuill K,
    3. Kendrick AH
    . Does the six-minute walk test predict survival at one year and in the longer term in patients idiopathic pulmonary fibrosis (IPF)? Thorax 2016;71(Suppl 3):A239–A240.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Nishiyama O,
    2. Taniguchi H,
    3. Kondoh Y,
    4. Kimura T,
    5. Kato K,
    6. Ogawa T,
    7. et al
    . Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Resp Med 2007;101(4):833–838.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Hardinge M,
    2. Annandale J,
    3. Bourne S,
    4. Cooper B,
    5. Evans A,
    6. Freeman D,
    7. et al
    ; British Thoracic Society Home Oxygen Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70(Suppl 1):i1–i43.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. McDonald CF,
    2. Whyte K,
    3. Jenkins S,
    4. Serginson J,
    5. Frith P
    . Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand. Respirology 2016;21(1):76–78.
    OpenUrl
  10. 10.↵
    1. Sharp C,
    2. Adamali H,
    3. Millar AB
    . Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev 2016;7:CD011716.
    OpenUrl
  11. 11.↵
    1. Bell EC,
    2. Cox NS,
    3. Goh N,
    4. Glaspole I,
    5. Westall GP,
    6. Watson A,
    7. Holland AE
    . Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017;26(143). pii: 160080.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Visca D,
    2. Mori L,
    3. Tsipouri V,
    4. Canu S,
    5. Bonini M,
    6. Pavitt M,
    7. et al
    . AmbOx: a randomised controlled, crossover trial evaluating the effects of ambulatory oxygen on health status in patients with fibrotic interstitial lung disease. Am J Resp Crit Care 2017;195:A7603.
    OpenUrl
  13. 13.↵
    1. Holland AE,
    2. Spruit MA,
    3. Troosters T,
    4. Puhan MA,
    5. Pepin V,
    6. Saey D,
    7. et al
    . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44(6):1428–1446.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Corte TJ,
    2. Wort SJ,
    3. Talbot S,
    4. Macdonald PM,
    5. Hansell DM,
    6. Polkey M,
    7. et al
    . Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2012;29(1):41–50.
    OpenUrlPubMed
  15. 15.↵
    1. Lettieri CJ,
    2. Nathan SD,
    3. Browning RF,
    4. Barnett SD,
    5. Ahmad S,
    6. Shorr AF
    . The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006;100(10):1734–1741.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Agustí AG,
    2. Roca J,
    3. Gea J,
    4. Wagner PD,
    5. Xaubet A,
    6. Rodriguez-Roisin R
    . Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991;143(2):219–225.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Risk C,
    2. Epler GR,
    3. Gaensler EA
    . Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984;85(1):69–74.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Raghu G,
    2. Nathan SD,
    3. Behr J,
    4. Brown KK,
    5. Egan JJ,
    6. Kawut SM,
    7. et al
    . Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015;46(5):1370–1377.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Boutou AK,
    2. Pitsiou GG,
    3. Trigonis I,
    4. Papakosta D,
    5. Kontou PK,
    6. Chavouzis N,
    7. et al
    . Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology 2011;16(3):451–458.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    1. Fulmer JD,
    2. Roberts WC,
    3. von Gal ER,
    4. Crystal RG
    . Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979;63(4):665–676.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.
    1. Agusti AG,
    2. Roca J,
    3. Rodriguez-Roisin R,
    4. Xaubet A,
    5. Agusti-Vidal A
    . Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988;1(6):510–516.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Chinet T,
    2. Jaubert F,
    3. Dusser D,
    4. Danel C,
    5. Chrétien J,
    6. Huchon GJ
    . Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. Thorax 1990;45(9):675–678.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Noble PW,
    2. Albera C,
    3. Bradford WZ,
    4. Costabel U,
    5. Glassberg MK,
    6. Kardatzke D,
    7. et al
    .; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760–1769.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. King TE Jr.,
    2. Bradford WZ,
    3. Castro-Bernardini S,
    4. Fagan EA,
    5. Glaspole I,
    6. Glassberg MK,
    7. et al
    .; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083–2092.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Hyldgaard C
    . A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival. Dan Med J 2015;62(4):B5069.
    OpenUrl
  26. 26.↵
    1. Siebeling L,
    2. Puhan MA,
    3. Muggensturm P,
    4. Zoller M,
    5. Ter Riet G
    . Characteristics of Dutch and Swiss primary care COPD patients – baseline data of the ICE COLD ERIC study. Clin Epidemiol 2011;3:273–283.
    OpenUrlPubMed
  27. 27.↵
    1. Tashkin DP,
    2. Celli B,
    3. Senn S,
    4. Burkhart D,
    5. Kesten S,
    6. Menjoge S,
    7. Decramer M
    ; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543–1554.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Wise RA,
    2. Anzueto A,
    3. Cotton D,
    4. Dahl R,
    5. Devins T,
    6. Disse B
    ; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369(16):1491–1501.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Lacasse Y,
    2. Bernard S,
    3. Maltais F
    . Eligibility for home oxygen programs and funding across Canada. Can Respir J 2015;22(6):324–330.
    OpenUrl
  30. 30.↵
    1. Khor YH,
    2. Goh NSL,
    3. McDonald CF,
    4. Holland AE
    . Oxygen therapy for interstitial lung disease: physicians' perceptions and experiences. Ann Am Thorac Soc 2017;14(12):1772–1778.
    OpenUrl
  31. 31.↵
    1. Eaton T,
    2. Garrett JE,
    3. Young P,
    4. Fergusson W,
    5. Kolbe J,
    6. Rudkin S,
    7. Whyte K
    . Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002;20(2):306–312.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Khor YH,
    2. Goh NSL,
    3. McDonald CF,
    4. Holland AE
    . Oxygen therapy for interstitial lung disease: a mismatch between patient expectations and experiences. Ann Am Thorac Soc 2017;14(6):888–895.
    OpenUrl
  33. 33.↵
    1. Villalba WO,
    2. Sampaio-Barros PD,
    3. Pereira MC,
    4. Cerqueira EM,
    5. Leme CA Jr..,
    6. Marques-Neto JF,
    7. Paschoal IA
    . Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131(1):217–222.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.
    1. Delourme J,
    2. Stervinou-Wemeau L,
    3. Salleron J,
    4. Grosbois JM,
    5. Wallaert B
    . Six-minute stepper test to assess effort intolerance in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2012;29(2):107–112.
    OpenUrl
  35. 35.↵
    1. Jenkins S,
    2. Čečins N
    . Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. Intern Med J 2011;41(5):416–422.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Poulain M,
    2. Durand F,
    3. Palomba B,
    4. Ceugniet F,
    5. Desplan J,
    6. Varray A,
    7. Préfaut C
    . 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest 2003;123(5):1401–1407.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.
    1. Hsia D,
    2. Casaburi R,
    3. Pradhan A,
    4. Torres E,
    5. Porszasz
    . Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J 2009;34(3):605–615.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Mahler DA,
    2. Gifford AH,
    3. Waterman LA,
    4. Ward J,
    5. Machala S,
    6. Baird JC
    . Mechanisms of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest 2011;140(2):351–358.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Solway S,
    2. Brooks D,
    3. Lacasse Y,
    4. Thomas S
    . A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001;119(1):256–270.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Enright PL,
    2. McBurnie MA,
    3. Bittner V,
    4. Tracy RP,
    5. McNamara R,
    6. Arnold A,
    7. Newman AB
    ; Cardiovascular Health Study. The 6-min walk test: a quick measure of functional status in elderly adults. Chest 2003;123(2):387–398.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords